Roivant Sciences

Day One Reports First Quarter 2023 Financial Results and Corporate Progress

Retrieved on: 
Monday, May 1, 2023
Rituximab, Bevacizumab, Society, Drug development, Capecitabine, New Drug Application, Roche, Neogene, Food and Drug Administration, Clinical trial, NDA, Cancer, MAPK, SNO, MBA, MEK, CMO, CCO, Doctor of Philosophy, ASCO, Research and development, Pakistan Society of Neuro-Oncology, Goldman Sachs, Development, American Society of Clinical Oncology, MD, Patient, Investment, Pediatrics, Roivant Sciences, Annual general meeting, Webcast, FDA, Conference, Day One, ASPHO, D, Pharmaceutical industry, Nursing, Medical imaging, Video game, Genentech, Research

BRISBANE, Calif., May 01, 2023 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced its first quarter 2023 financial results and highlighted recent corporate achievements.

Key Points: 
  • The company remains in position to initiate the submission of the NDA as early as the second quarter of 2023.
  • R&D Expenses: Research and development expenses were $27.8 million for the first quarter of 2023 compared to $15.0 million for the first quarter of 2022.
  • G&A Expenses: General and administrative expenses were $18.0 million for the first quarter of 2023 compared to $12.7 million for the first quarter of 2022.
  • Day One will present two posters at the 2023 American Society of Pediatric Oncology/Hematology (ASPHO) Conference May 10-13, 2023, focused on the pLGG burden of illness and healthcare utilization data.

Lokavant Launches Inaugural Product Advisory Board to Drive Strategic Direction of AI-Based Clinical Trial Predictive Technology

Retrieved on: 
Wednesday, April 26, 2023
Software, Research, Professional Services, Pharmaceutical, Technology, Artificial Intelligence, Health Technology, Data Analytics, Clinical Trials, Science, Biotechnology, Health, Pharmacy, Digital performance, Drug development, Senior, Clinical trial, Innovation, Roivant Sciences, Bristol Myers Squibb, Growth, Pharmaceutical industry, Management

Lokavant, the clinical trial intelligence platform company, today announced its Product Advisory Board.

Key Points: 
  • Lokavant, the clinical trial intelligence platform company, today announced its Product Advisory Board.
  • The Lokavant Product Advisory Board brings together accomplished leaders in pharmaceutical research and development who are experts in global clinical trials and related operations.
  • Lokavant’s advisory board meets regularly to share feedback on the clinical research market landscape, customer needs, product capabilities and Lokavant’s strategic platform roadmap.
  • “Our Product Advisory Board’s expertise and insights will be invaluable as we drive greater predictability in clinical trial performance, generating value for all stakeholders in clinical research.”

Finch Therapeutics Announces Executive Leadership Transitions

Retrieved on: 
Tuesday, April 25, 2023
Danforth, Teva Pharmaceuticals, Cleary Gottlieb Steen & Hamilton, Intellectual property, BS, University, Cleary, Washington College of Law, Case Western Reserve University, Research, Genentech, Doctor of Philosophy, PwC, MS, Eli Lilly, Bristol Myers Squibb, Bentley University, Johns Hopkins University, Patient, CPA, Invention, CFO, FNCH, Therapy, Chemical engineering, Management, Pharmaceutical industry, Biotechnology, Finch, Roivant Sciences

SOMERVILLE, Mass., April 25, 2023 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch”, “Finch Therapeutics” or the “Company”) (Nasdaq: FNCH), a microbiome technology company with a portfolio of intellectual property and microbiome assets, today announced the appointment of Matthew P. Blischak as Chief Executive Officer, effective May 16, 2023. In conjunction with the appointment of Mr. Blischak, Mark Smith, PhD, will conclude his role as Chief Executive Officer and as a member of the Company’s board of directors, effective May 15, 2023. Dr. Smith is expected to remain engaged with the Company as a scientific and strategic advisor. In addition, Finch announced the appointment of Lance Thibault as Chief Financial Officer, effective May 16, 2023. In conjunction with the appointment of Mr. Thibault, Marc Blaustein will conclude his role as Chief Operating Officer and as the Company’s principal financial officer, effective May 15, 2023. Mr. Blaustein is expected to remain engaged with the Company as a strategic advisor.

Key Points: 
  • In addition, Finch announced the appointment of Lance Thibault as Chief Financial Officer, effective May 16, 2023.
  • “It is my privilege to welcome Matt as our next Chief Executive Officer.
  • “I am thrilled with the opportunity to lead Finch through this next stage in the Company’s journey,” said Matthew Blischak, incoming Chief Executive Officer of Finch Therapeutics.
  • His leadership has been critical in positioning the Company for success in this next chapter of our journey.”

Leading National Prostate Cancer Nonprofit Announces Return of Annual Run/Walk Series

Retrieved on: 
Tuesday, April 25, 2023
Survivor, Prostate cancer, Friends, Revlon Run Walk, ZERO—The End of Prostate Cancer, ZERO, AstraZeneca, Athlete, Bayer, Lilly, Patient, Physician, Roivant Sciences, City, Disease, Caregiver, Dairy, Pharmaceutical industry, Event

WASHINGTON, April 25, 2023 /PRNewswire/ -- ZERO Prostate Cancer is proud to announce the return of its annual celebration of prostate cancer patients, survivors, caregivers, and families with its national Run/Walk series. This year, ZERO joins forces with fifty U.S. cities in the upcoming ZERO Prostate Cancer Run/Walk series.

Key Points: 
  • WASHINGTON, April 25, 2023 /PRNewswire/ -- ZERO Prostate Cancer is proud to announce the return of its annual celebration of prostate cancer patients, survivors, caregivers, and families with its national Run/Walk series .
  • This year, ZERO joins forces with fifty U.S. cities in the upcoming ZERO Prostate Cancer Run/Walk series.
  • "As the largest men's health event series in the world, the ZERO Prostate Cancer Run|Walk series shares hope, inspires action, and builds community among patients and the people who love them," said Jamie Bearse, ZERO Prostate Cancer's CEO.
  • "We are thrilled to have fifty communities nationwide that have committed to raising significant funds and awareness, building local prostate cancer communities, and ending prostate cancer," said Tracy Cesaretti, ZERO Prostate Cancer's Vice President of Events.

Lokavant Hires Experienced Leaders to Accelerate Growth Trajectory

Retrieved on: 
Tuesday, April 4, 2023
Research, Apps, Applications, Technology, Clinical Trials, Professional Services, Software, Data Analytics, Pharmaceutical, Health, Science, Mills, GSK plc, IBM, Meredith, SOCOM U.S. Navy SEALs: Confrontation, Marketing, Clinical trial, ICON, Intelligence, Science 37, Roivant Sciences, ERT, Patient, News, Management, Pharmaceutical industry

Lokavant, the clinical trial intelligence platform company, announces strategic new hires to drive its mission to make clinical trials smarter.

Key Points: 
  • Lokavant, the clinical trial intelligence platform company, announces strategic new hires to drive its mission to make clinical trials smarter.
  • Mills worked previously as global vice president of sales for Clario, and in various commercial leadership roles at ICON.
  • “Having been in the industry for over 20 years, I have not seen a more exciting company than Lokavant come to market,” said Mills.
  • Weatherhead came to Lokavant from Castor, a provider of decentralized clinical trial technology, where he was vice president of marketing.

Lokavant Emerges from Roivant Sciences with Multiple Industry Partnerships to Accelerate Impact on Clinical Research

Retrieved on: 
Tuesday, April 4, 2023
Data Management, Biotechnology, Technology, Health, Pharmaceutical, Health Technology, Other Science, Research, Software, Science, Clinical Trials, Drug development, Therapy, Marketing, Clinical trial, Intelligence, Roivant Sciences, Multimedia, Parexel, Patient, Growth, Unified interoperability, News, ChromeOS, Pharmaceutical industry, Fine chemical

View the full release here: https://www.businesswire.com/news/home/20230404005405/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20230404005405/en/
    Lokavant emerges from Roivant Sciences to Accelerate Impact on Clinical Research (Graphic: Business Wire)
    Through incubation within Roivant Health, Lokavant identified a broader market opportunity to solve a longstanding problem in clinical trials for sponsors and contract research organizations (CROs).
  • “The ability to continuously innovate is central to clinical development,” said Peyton Howell, Parexel Chief Operating & Growth Officer.
  • Lokavant’s platform unifies data in real time across all trial functions to power a machine-learning engine that anticipates clinical trial events and their impact on trial execution.
  • “Our intelligence platform is proven, built on a trusted and growing proprietary database of clinical research data from more than 2,000 trials.

Sumitomo Pharma Subsidiary Companies in the U.S., Including Sunovion, to Combine and Form Sumitomo Pharma America

Retrieved on: 
Monday, April 3, 2023
Biotechnology, Pharmaceutical, Health, Central nervous system, Sunovion, Sumitomo Pharma, Research, Phajo Drugom Zhigpo, Patient, Roivant Sciences, Therapy, Urology, Fine chemical, Pharmaceutical industry

Sunovion Pharmaceuticals Inc., an indirect, wholly owned subsidiary of Sumitomo Pharma Co. Ltd, announced today that it will combine with affiliate companies Sumitomo Pharma America Holdings, Inc., Sumitovant Biopharma Ltd., Myovant Sciences, Inc., Urovant Sciences, Inc., Enzyvant Therapeutics, Inc., and Sumitomo Pharma Oncology, Inc. to form Sumitomo Pharma America, Inc. effective July 1, 2023.

Key Points: 
  • Sunovion Pharmaceuticals Inc., an indirect, wholly owned subsidiary of Sumitomo Pharma Co. Ltd, announced today that it will combine with affiliate companies Sumitomo Pharma America Holdings, Inc., Sumitovant Biopharma Ltd., Myovant Sciences, Inc., Urovant Sciences, Inc., Enzyvant Therapeutics, Inc., and Sumitomo Pharma Oncology, Inc. to form Sumitomo Pharma America, Inc. effective July 1, 2023.
  • Spirovant Sciences, Inc., Sumitovant’s remaining wholly owned subsidiary, will operate as a standalone company under Sumitomo Pharma America.
  • Sumitovant’s current CEO Myrtle Potter will serve as President and CEO of Sumitomo Pharma America upon completion of the combination.
  • Hiroshi Nomura, President and CEO of Sumitomo Pharma, said, “We remain deeply committed to addressing pressing health challenges and believe Sumitomo Pharma America will serve as a valuable growth engine.

Roivant Reports Positive Topline Results from ADORING 2 Atopic Dermatitis Phase 3 Trial of VTAMA® (tapinarof) Cream, 1% Once Daily in Adults and Children as Young as 2 Years Old

Retrieved on: 
Wednesday, March 15, 2023
Linda, 2020 Henry Ford Health System 200, Adolescence, Pediatrics, Quality of life, Atopic dermatitis, Itch, Psoriasis, BSA, Clinical research, Dermatitis, Body surface area, Roivant Sciences, Patient, Rady, Physician, FDA, Pharmacist, Diagnosis, Prescription, JD, Week, Plaque, Surveying, Pharmaceutical industry, Cosmetics, Dietary supplement, EASI, MD, Dermatology

“Atopic dermatitis, the most common type of eczema, affects more than 9.6 million children and 16.5 million adults in the United States.

Key Points: 
  • “Atopic dermatitis, the most common type of eczema, affects more than 9.6 million children and 16.5 million adults in the United States.
  • In the U.S., VTAMA cream is already approved for the topical treatment of plaque psoriasis in adults.
  • Importantly, VTAMA cream data indicated no safety or tolerability signals in this population including children as young as 2 years old.
  • “Atopic dermatitis can have a negative impact on the quality of life of diagnosed children as well as their families.

Roivant to Host Investor Call at 8:00 AM ET on Wednesday, March 15 to Review Results from ADORING 2 Phase 3 Trial in Atopic Dermatitis

Retrieved on: 
Tuesday, March 14, 2023
Atopic dermatitis, Roivant Sciences, Webcast, Cryptocurrency, Online shopping

BASEL, Switzerland and LONDON and NEW YORK and BOSTON, March 14, 2023 (GLOBE NEWSWIRE) -- Roivant Sciences (Nasdaq: ROIV) today announced that it will host a live investor call and webcast at 8:00 AM ET on Wednesday, March 15 to review topline results from the ADORING 2 study, one of two replicate Phase 3 studies in atopic dermatitis.

Key Points: 
  • BASEL, Switzerland and LONDON and NEW YORK and BOSTON, March 14, 2023 (GLOBE NEWSWIRE) -- Roivant Sciences (Nasdaq: ROIV) today announced that it will host a live investor call and webcast at 8:00 AM ET on Wednesday, March 15 to review topline results from the ADORING 2 study, one of two replicate Phase 3 studies in atopic dermatitis.
  • To access the call by phone, please register online using this registration link .
  • A webcast of the call will also be available under “Events & Presentations” in the Investors section of the Roivant website at https://investor.roivant.com/news-events/events .
  • The archived webcast will be available on Roivant’s website after the call.

Proteovant Therapeutics to Present Preclinical Data from Estrogen Receptor and IKZF2 Protein Degrader Programs

Retrieved on: 
Tuesday, March 14, 2023
Conference, Disorder, Roivant Sciences, Congress, IKZF2, Proteolysis, Therapy, Endoplasmic-reticulum-associated protein degradation, Patient, Vaccine

Targeted protein degradation harnesses the body’s natural protein disposal system and offers the potential to develop new medicines targeting historically difficult-to-drug proteins that play an important role in causing serious diseases.

Key Points: 
  • Targeted protein degradation harnesses the body’s natural protein disposal system and offers the potential to develop new medicines targeting historically difficult-to-drug proteins that play an important role in causing serious diseases.
  • Proteovant Therapeutics is discovering and developing best-in-class and first-in-class degraders that can engage previously undruggable targets.
  • “PVTX-321, our degrader targeting the estrogen receptor, is highly potent and demonstrates impressive, dose dependent tumor growth inhibition and shrinkage in preclinical models.
  • In addition, PVTX-405 has best-in-class potential with robust IKZF2 degradation in vivo.